A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: This study will assess the safety and efficacy of Endostar combined with chemotherapy in osteosarcoma patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
• Treatments: Endostar protein

Criteria

Inclusion Criteria:

• Patients with histologically confirmed osteosarcoma, who have no evidence of metastasis

• At least one measurable lesion

• Life expectancy > 3 months

• ECOG performance status 0-2

• Adequate hematologic, cardiac, renal, and hepatic function

• Patients with prior chemotherapy should have at least 4 weeks clearance period before entering this study

Exclusion Criteria:

• Evidence of metastasis

• Serious infection

• Evidence of bleeding diathesis

• Significant cardiovascular disease

• Pregnant or lactating woman

• Allergic to E.coli preparation